Biological characteristics and outcomes of gliosarcoma by Hashmi, Fauzan Alam et al.
eCommons@AKU
Section of Neurosurgery Department of Surgery
August 2018
Biological characteristics and outcomes of
gliosarcoma
Fauzan Alam Hashmi
Aga Khan University, fauzan.alam@aku.edu
Adnan Salim
Aga Khan University
Muhammad Shahzad Shamim
Aga Khan University, shahzad.shamim@aku.edu
Muhammad Ehsan Bari
Aga Khan University, ehsan.bari@aku.edu
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_neurosurg
Recommended Citation
Hashmi, F. A., Salim, A., Shamim, M., Bari, M. (2018). Biological characteristics and outcomes of gliosarcoma. Journal of the Pakistan
Medical Association, 68(8), 1273-1275.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_neurosurg/152
Abstract
Gliosarcoma is a highly aggressive primary brain tumour. It is
a relatively rare tumour and comprises of two histological
components, glial and sarcomatous. Gliosarcomas carry a
poorer prognosis than that of Glioblastoma Multiforme
(GBM). The current review highlights important histological
and radiological features of gliosarcoma in the light of recent
literature, and also touches upon the treatment options and
outcomes of various types of gliosarcoma.
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Review of Evidence
Gliosarcoma is a rare primary brain tumour with prevalence
varying from 1.5-8% in different studies, and accounts for
0.48% of all intra-cranial tumours.1 It can be further sub-
classified into primary gliosarcoma (PGS) and secondary
gliosarcoma (SGS), and whereas PGS occurs de novo, SGS is
believed to occur as a recurrence or progression of
Glioblastoma Multiforme (GBM), or as a consequence of
radiation therapy.2
The current accepted definition of gliosarcoma is 'a well-
circumscribed lesion with clearly identifiable biphasic glial and
metaplastic mesenchymal components'.3,4 The glial
component resembles GBM and is richly positive for glial
fibrillary acidic protein (GFAP),while the sarcomatous
component resembles fibrosarcoma, but may also resemble
osteosarcoma, chondrosarcoma, angiosarcoma,or
rhabdomyosarcoma,5,6 and is rich in reticulin and poor in GFAP
expression. Reis et al., observed that P53 mutation is seen in
23% of gliosarcomas as compared to 11% of primary GBM, and
epidermal growth factor receptor (EGFR) amplification, is found
in only 4% of gliosarcomas compared to 35% of GBM. Small
differences are also noted in Phosphatase and Tensin homolog
(PTEN) mutation and cyclin-dependent kinase (CDK)
amplification.7 Cases of radiation induced gliosarcoma include
ependymoma, oligodendroglioma, anaplastic astrocytoma,
meningioma, pituitary adenoma, acute lymphoblastic
leukaemia and choriocarcinoma. Extracranial metastasis can be
seen in patients with SGS.2,8,9
Radiologically, Zhang et al., reported gliosarcomas as irregular
masses on both CT and MRI, with a smooth external wall, well
demarcated from the surrounding brain parenchyma, and
significant surrounding oedema. Furthermore, they described
that gliosarcomas occur more commonly in the temporal lobe,
and can appear similar to meningiomas on gross morphology.10
Han et al.,3 described it as generally large lesions that are hypo-
intense on T1-weighted images and hyper-intense on T2-
weighted images, with areas of necrosis and central calcification
(characterized by heterogenous contrast enhancement), and
intense peripheral or irregular enhancement and shift of midline
structures. Diffusion and mass diffusion coefficient are usually
heterogeneous and MR spectroscopy may show choline (Cho)
peak, with normal creatinine (Cr) and low N-acetyl-aspartate
(NAA), although these findings are non-specific.11 Despite small
differences, gliosarcoma is largely indistinguishable from GBM
in most cases as they share identical radiological and clinical
characteristics, and their definitive differentiation is based only
on histopathology.4,12
The treatment is on the same lines as GBM, with maximal safe
resection as the cornerstone, followed by Concomitant
Chemotherapy and Radiation Therapy (CCRT).13 Castelli et al.,
reported their management of gliosarcoma patients with12-
months median follow up (2-71 months), and reported Gross
total resection (GTR) in 59% patients. Temozolamide based
CCRT was administered in 64% patients while 15% patients
received adjuvant chemotherapy regimens based on
platinum, fotemustine and vincristine. Treatment at
recurrence included chemotherapy in 80% of patients, repeat
surgery in 17% and chemo-radiotherapy in 2% of the
patients.14 They report a median Overall Survival (OS) of 13
months, and a median Progression Free Survival (PFS) of 7
months. Although it is difficult to conclude as such but CCRT
and adjuvant chemotherapy did not improve OS compared
to radiotherapy alone. High dose of Radiation Therapy (RT)
and salvage treatment appeared to increase OS.14
Cachia et al., in their series reported GTR in 53 % patients and
CCRT in 70% of patients. Bevacuzimab based regimens were
used in 47% of patients, with half receiving single agent and
half another agent in combination.8 Patients with GTR had a
better Overall Survival (OS) (24.7 vs. 10.1 months), although
this did not reach statistical significance. Overall, patients
treated with bevacizumab had a PFS of 4.2 months and an OS
of 8.7 months from initiation of treatment. Patients with PGS
had the same outcomes, however, SGS patients treated with
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bevacizumab, had a OS of 7.3 months and PFS of 3.8 months.8
Treatment with bevacuzimab along with temozolamide
based CCRT did not show any benefit in OS of patients with
SGS.8
Kozak et al., also reported a median OS of 9 months. Age at
presentation, extent of resection, and adjuvant RT were
significantly associated with better survival.15 SGS patients
were defined as those with a prior history of GBM, and in this
sub-group PFS was 3.1 months from the time of sarcomatous
transformation.8 Twenty-one percent of patients developed
tumour metastases and 15% showed leptomeningeal
dissemination. Extra-axial spread occurred to the
infratemporal region outside the temporal bone, cervical
lymph nodes, and temporal bone. The cumulative OS of PGS
and SGS was 17.5 months and PFS was 6.5 months. 
There appears a wide variation in reported OS for gliosarcoma
patients, from 4-11.5 months.3,5 Interestingly, the OS for SGS
is 25 months, and is the same as PGS if measured from the
time of first diagnosis of GBM.
Conclusion
Gliosarcoma is a rare tumour that is difficult to differentiate
from GBM on clinical or radiological information although can
be differentiated on histopathology. GTR followed by
temozolamide based CCRT may provide the best outcome.
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Figure: a) T1WI showing iso-hypo-intense lesion in left parieto-temporal region. b) T2WI showing hyper-intense lesion in left parieto-temporal region. c) T1- contrast enhanced image
showing heterogenous enhancement.
